Diseases in 2000

Companies are racing to keep pace with the emergence of drug-resistant microorganisms.

With asthma cases on the rise, a better understanding of the disease on the molecular and systems levels promises more efficacious treatments.

Prognostic/diagnostic testing and a raft of new drug targets from genomics promise to transform cardiovascular medicine.

Together with major international initiatives, companies are launching an offense against the world's most deadly parasitic disease.

The need for new treatments for AIDS is more urgent than ever.

Rapid progress in our understanding of immune function promises more effective treatments for autoimmune disorders.

Progress in understanding the molecular basis of drug resistance in cancer promises more effective treatments.

The aging populations of developed countries are likely to present a growing market for arthritis therapies.